share_log

6-K: Arexvy, Gsk's Respiratory Syncytial Virus Vaccine, Receives Positive European Medicines Agency Chmp Opinion for Adults Aged 50-59 at Increased Risk for Rsv Disease

6-K: Arexvy, Gsk's Respiratory Syncytial Virus Vaccine, Receives Positive European Medicines Agency Chmp Opinion for Adults Aged 50-59 at Increased Risk for Rsv Disease

6-K:葛兰素史克公司的RSV疫苗Arexvy获得欧洲药品管理局CHMP的积极评价,适用于50-59岁患RSV疾病风险较高的成年人
美股sec公告 ·  07/29 06:19
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息